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PDoes Erectile Dysfunction Contribute
to Cardiovascular Disease Risk Prediction
Beyond the Framingham Risk Score?
Andre B. Araujo, PHD,* Susan A. Hall, PHD,* Peter Ganz, MD,† Gretchen R. Chiu, MS,*
Raymond C. Rosen, PHD,* Varant Kupelian, PHD,* Thomas G. Travison, PHD,*
John B. McKinlay, PHD*
Watertown, Massachusetts; and San Francisco, California
Objectives This study was designed to determine whether erectile dysfunction (ED) predicts cardiovascular disease (CVD)
beyond traditional risk factors.
Background Both ED and CVD share pathophysiological mechanisms and often co-occur. It is unknown whether ED improves
the prediction of CVD beyond traditional risk factors.
Methods This was a prospective, population-based study of 1,709 men (of 3,258 eligible) age 40 to 70 years. The ED
data were measured by self-report. Subjects were followed for CVD for an average follow-up of 11.7 years. The
association between ED and CVD was examined using the Cox proportional hazards regression model. The dis-
criminatory capability of ED was examined using C statistics. The reclassification of CVD risk associated with ED
was assessed using a method that quantifies net reclassification improvement.
Results Of the prospective population, 1,057 men with complete risk factor data who were free of CVD and diabetes at
baseline were included. During follow-up, 261 new cases of CVD occurred. We found ED was associated with
CVD incidence controlling for age (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.05 to 1.90), age and
traditional CVD risk factors (HR: 1.41, 95% CI: 1.05 to 1.90), as well as age and Framingham risk score (HR:
1.40, 95% CI: 1.04 to 1.88). Despite these significant findings, ED did not significantly improve the prediction of
CVD incidence beyond traditional risk factors.
Conclusions Independent of established CVD risk factors, ED is significantly associated with increased CVD incidence. None-
theless, ED does not improve the prediction of who will and will not develop CVD beyond that offered by tradi-
tional risk factors. (J Am Coll Cardiol 2010;55:350–6) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.058s
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prectile dysfunction (ED) affects approximately 18 million
en age 20 years or older in the U.S. (1). Projections from
.S. prevalence data indicate that by 2025, over 300 million
en worldwide will have ED (2). The relationship between
D and cardiovascular disease (CVD) has received substan-
ial attention. The prevailing notion is that ED may serve as
sentinel marker for CVD (3–13). This is based largely on
rom the *New England Research Institutes, Watertown, Massachusetts; and the
Division of Cardiology, San Francisco General Hospital, University of California–
an Francisco, San Francisco, California. Supported by the following grants: #AG
4673 from the National Institute on Aging; #DK 44995 and #DK 51345 from the
ational Institute of Diabetes and Digestive and Kidney Disorders; and an unre-
tricted educational grant to NERI from Bayer Healthcare. Dr. Hall is a former
mployee of and former consultant to GlaxoSmithKline, but has no equity interest in
laxoSmithKline. Dr. Ganz serves as a consultant to GlaxoSmithKline, Genentech,
nd Pfizer. Dr. Rosen serves as a consultant to Bayer-Schering, Eli Lilly, and Pfizer.m
Manuscript received May 22, 2009; revised manuscript received August 26, 2009,
ccepted August 30, 2009.hared pathophysiological mechanisms (e.g., endothelial
ysfunction, arterial occlusion, systemic inflammation)
3,6,9,14–19) and risk factors (6,20–25), the high copreva-
ence of both conditions (8,10,26–28), and the reasonable
remise that progressive occlusive disease should manifest
arlier in the microvasculature than in larger vessels (9,29).
rospective studies have shown that ED predicts the devel-
pment of CVD (30–33) and CVD mortality (34). Of
articular interest is the observation that the risk of CVD
ssociated with ED is in the range of risk associated with
raditional CVD risk factors (31,32,34), such as current
moking, hypertension, or a family history of myocardial
nfarction. However, it is not known whether ED improves
he prediction of CVD beyond traditional risk factors. We
ought to test the hypothesis that ED improves CVD risk
rediction. Confirmation of this hypothesis would have
ajor clinical and public health implications in light of the
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January 26, 2010:350–6 Does ED Improve CVD Risk Prediction?bservation that sudden death may be the first manifestation of
VD (35–37).
ethods
ample. The MMAS (Massachusetts Male Aging Study)
s a prospective, observational cohort study of aging, health,
nd endocrine and sexual function in a population-based
andom sample of men between the ages 40 and 70 years
38). A total of 1,709 respondents (52% of 3,258 eligible)
ompleted the baseline (1987 to 1989) protocol. The
MAS subjects were observed again from 1995 to 1997
n  1,156, 77% response rate) and 2002 to 2004 (n  853,
5% response rate). These response rates were expected
iven the requirements for early morning phlebotomy and
xtensive in-person interviews. Subjects received no finan-
ial incentive at baseline, and $50 and $75 remunerations at
he first and second follow-ups, respectively.
rotocol. Extensive details on MMAS have been pub-
ished elsewhere (38). The core field protocol for MMAS
emained the same over time. A trained field technician/
hlebotomist visited each subject at home, administered a
ealth questionnaire, and obtained 2 nonfasting blood
amples. Anthropometrics (height, weight, hip and waist
ircumference) and blood pressure were directly measured
ccording to standard protocols developed for large-scale
eldwork (39). Two nonfasting blood samples were drawn
nd serum was pooled for analysis. High-density lipoprotein
holesterol (HDL-C) was measured at a Centers for Dis-
ase Control and Prevention-certified lipid laboratory
Miriam Hospital, Providence, Rhode Island). The follow-
ng information was collected via interviewer-administered
uestionnaire: demographics, psychosocial factors, history
f chronic disease, self-assessed general health status, to-
acco and alcohol use, nutritional intake, and physical
ctivity/energy expenditure during the past 7 days. MMAS
eceived institutional review board approval and all subjects
ave written informed consent.
ovariates. Established CVD risk factors were used to
ontrol for confounding. The following were input as
ontinuous variables: age, body mass index, HDL-C, and
otal cholesterol. In addition, we adjusted for current smok-
ng (yes/no) and hypertension categorized according to
lood pressure readings by the Joint National Committee on
etection, Evaluation, and Treatment of High Blood Pres-
ure definition (40). Also, we constructed the Framingham
isk score, which gives the 10-year estimated probability of
coronary heart disease (CHD) event according to Adult
reatment Panel III guidelines (41).
D. At the end of the interview, the subject was given a
3-item questionnaire on sexual activity to be completed in
rivate and returned in a sealed envelope (42). The ques-
ionnaire included 13 items related to ED, such as, “During
he last 6 months have you ever had trouble getting an
rection before intercourse begins?” The 13 items were
ombined in a discriminant-analytic formula to assign a tegree of erectile function to
ach subject (43). The same dis-
riminant formula was used at
oth baseline and follow-up.
Calibration data for the discrimi-
ant formula were taken from an
dditional single-question, subjec-
ive self-assessment of ED, included
n the follow-up questionnaire in
esponse to recommendations of the
ational Institutes of Health Con-
ensus Panel (44). Impotence was
efined as “being unable to get and
eep an erection that is rigid enough
or satisfactory sexual activity.” The
ubject rated himself as completely
mpotent (“never able to get and
eep an erection . . .”), moderately impotent (“sometimes able
. .”), minimally impotent (“usually able . . .”), or not impotent
“always able . . .”). In random subsets of the follow-up
amples the self-assessment was validated (45) against 2
stablished ED measures, the International Index of Erec-
ile Function (46) (r  0.71, n  254) and the Brief Male
exual Function Inventory (47) (r  0.78, n  251), as well
s an independent urologic assessment (48). As we have
one in previous analyses (23,26,49), we analyzed both the
-category ED status variable and also a binary ED status
ariable (absence/presence) that was defined as moderate or
omplete ED.
VD. Data on CVD were obtained from 3 sources: self-
eports, linkage of the MMAS database with the National
eath Index (NDI) (50), and medical records. Self-reports
ncluded a wide range of major CVD end points (e.g.,
yocardial infarction, atherosclerosis, stroke, coronary ar-
ery bypass graft surgery, congestive heart failure). Subjects
ho gave positive endorsement of any of these were con-
idered to have CVD. Based on medical records (primary
ischarge diagnosis) and the NDI (underlying cause), CVD
as determined according to the International Classifica-
ion of Diseases (ICD). Before 1999, events/deaths were
oded according to the ICD-9th Revision and subse-
uently, according to the ICD-10th Revision. Subjects
ith the following codes were considered to have devel-
ped CVD: ICD-9/ICD-10 codes 390 to 459/I00 to I99,
hich include coronary heart disease, heart failure, pe-
ipheral vascular disease, cerebrovascular disease, and other
ascular diseases (51).
tatistical analysis. Person-years were accumulated from
ach subject’s baseline visit to date of last observation or
vent date. We computed incidence rates (cases/person-
ears) in each ED category, with 95% confidence intervals
CIs) estimated under the assumption that incidence rates
ollowed a Poisson distribution (52). A Kaplan-Meier
urvival curve was used to illustrate the association between
D and CVD. Hazard ratios (HRs) were calculated using
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
ED  erectile dysfunction
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
ICD  International
Classification of Diseases
NDI  National Death
Indexhe Cox proportional hazards regression model (53); men
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Does ED Improve CVD Risk Prediction? January 26, 2010:350–6ith no ED served as the reference group for the 4-category
D variable and men with no or minimal ED served as the
eference group for the binary ED variable. Tests for linear
rend across the 4-category ED variable were performed by
reating linear contrasts.
In order to address the question of whether ED contrib-
tes to the prediction of CVD, we conducted 3 sets of
nalyses. First, we fit multivariate Cox proportional hazards
egression models to examine the independent influence of
D. Second, we evaluated the discriminatory capability of
D and traditional risk factors using C statistics, which is
n extension of the traditional receiver-operator character-
stic curve analysis to survival analysis (54,55). Finally, we
ssessed the reclassification of CVD risk associated with ED
sing methods developed by Pencina et al. (56) that esti-
ated the net reclassification improvement. This method-
logy involved the fitting of 2 statistical models, the first
ncluding age and Framingham risk score, and a second that
dded ED. Based on this, we evaluated changes in Framing-
am risk category reclassification (57) separately for CVD
ases and noncases that occurred during the first 10 years of
ollow-up. The net reclassification improvement was com-
uted by summing the following quantities: 1) the difference
n proportions of individuals reclassified into a higher risk
ategory and the proportion reclassified into a lower risk
ategory among men who developed events; and 2) the
ifference in the proportion of individuals reclassified into a
ower risk category and the proportion reclassified into a
igher risk category among those who did not develop
vents. The significance of the net reclassification improve-
ent was assessed with an asymptotic test (56). We also
alculated an alternative index of discrimination that does
ot rely on category cut points, the integrated discrimina-
ion improvement, which can be viewed as a difference
etween improvement in average sensitivity and any poten-
ial increase in average 1 – specificity (56). We used SAS
ersion 9.2 (SAS Institute, Cary, North Carolina) for all
nalyses. Significance was considered present when p 
.05.
esults
he dataset included men with complete baseline risk factor
ata who were free of CVD and diabetes (a CHD risk
quivalent) at baseline. Of these 1,057 men, 261 (25.0%)
eveloped CVD. Of the 261 CVD cases, 200 were con-
rmed by either NDI or medical record and the remaining
1 were obtained by self-report only. Of 261 CVD events,
1 (27.2%) were fatal CVD events. Men without ED at
aseline (n  879) were followed for an average of 12.0
ears and men with ED (n  178) for 10.3 years.
Table 1 shows baseline characteristics of men according to
D status. Men with ED were older on average (age 59  8
ears) than men without ED (age 53 8 years). Among men
ith ED, prevalence of hypertension and smoking was higher.
en with ED also had slightly higher body mass index, lower sotal and HDL-C, higher systolic blood pressure, and higher
ramingham risk score. Overall, 37% of men with ED were in
he highest risk category for Framingham risk score, compared
ith 17% of men without ED.
Age-adjusted CVD incidence rates are shown in Table 2.
s expected, CVD incidence was strongly related to Fra-
ingham risk score. Data not shown provide no evidence to
uggest variation in the association between ED and CVD
ccording to age (interaction p values for ED by age
categorical or continuous] 0.5). Age-adjusted CVD in-
idence increased with ED severity in a nonmonotonic
ashion (p  0.08), with higher rates observed in men with
oderate and complete ED compared with men who had
o or minimal ED. For the binary ED variable, CVD
ncidence was 19.7 (95% CI: 17.3 to 22.5) per 1,000
erson-years among men with none/minimal ED compared
ith 26.9 (95% CI: 20.9 to 34.7) per 1,000 person-years
mong men with moderate/complete ED (p  0.02).
Table 3 shows the relationship between ED and CVD in
arious multivariate models. The assumption of propor-
ional hazards was met for these models. Adjusted for age,
D was significantly associated with CVD incidence (HR:
.42, 95% CI: 1.05 to 1.90, p  0.02). Further adjustment
or body mass index, HDL-C, total cholesterol, current
escriptive Characteristics ofnalytic Sample by Ba eline ED StatusTable 1 Descriptive Characteris ics ofAnalytic Sample by Baseline ED Status
Subjects Without ED
(n  879)
Subjects With ED
(n  178)
Age, yrs 53 (8) 59 (8)
Age group, yrs
40–49 368 (42) 33 (19)
50–59 316 (36) 46 (26)
60–70 195 (22) 99 (56)
Self-reported heart disease 0 (0) 0 (0)
Self-reported diabetes 0 (0) 0 (0)
Self-reported hypertension 216 (25) 59 (33)
JNC-V hypertension
Optimal 234 (27) 41 (23)
Normal 260 (30) 40 (22)
High normal 182 (21) 42 (24)
Stage I 152 (17) 41 (23)
Stage II–IV 51 (6) 14 (8)
Current smoking 204 (23) 52 (29)
Body mass index, kg/m2 27.0 (4.1) 27.3 (4.3)
Total cholesterol, mg/dl 209 (51) 206 (43)
HDL cholesterol, mg/dl 44.0 (13.8) 41.3 (13.8)
Systolic blood pressure, mm Hg 125 (15) 129 (17)
Framingham risk score 0.12 (0.09) 0.18 (0.11)
Framingham risk score categories, %
5 159 (18) 13 (7)
5–10 272 (31) 44 (25)
10–20 297 (34) 55 (31)
20 151 (17) 66 (37)
alues are n or mean (% or SD).
ED erectile dysfunction; HDL high-density lipoprotein; JNC-V Joint National Committee on
etection, Evaluation, and Treatment of High Blood Pressure.moking, and Joint National Committee on Detection,
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January 26, 2010:350–6 Does ED Improve CVD Risk Prediction?valuation, and Treatment of High Blood Pressure hyper-
ension categories decrease the HR slightly to 1.41 (95% CI:
.05 to 1.90, p  0.02). In addition, ED was significantly
ssociated with CVD when adjusted for age and Framing-
am risk score (HR: 1.40, 95% CI: 1.04 to 1.88, p  0.03).
n multivariate sensitivity analyses in which we included
nly men with CVD that was confirmed by medical record
r NDI (with self-reports considered nonevents) or fatal
VD events (with nonfatal CVD considered nonevents),
he HRs associated with ED were 1.37 (95% CI: 0.98 to
.90, p  0.07) and 1.34 (95% CI: 0.79 to 2.28, p  0.28),
espectively.
Table 4 shows the C statistics for CVD according to
arious multivariate models. The C statistic for the full
ultivariate model was 0.7068. Addition of ED to this
odel offered only a small improvement in the resulting C
tatistic to 0.7106. The same pattern was observed with the
ge and Framingham risk score model, where the addition
f ED caused the C statistic to increase from 0.6910 to
.6953.
Data on the number of subjects according to Framing-
am CVD risk category based on an age-adjusted regression
odel, with reclassification of risk category after inclusion
ge-Adjusted CVD Incidence Rates According to Framingham RiskTable 2 Age-Adjusted CVD Incidence Rates According to Fram
No. of
Events
No. of
Person-Years
All subjects 261 12,405
Framingham risk score categories, %
5 18 2,304
5–10 48 3,952
10–20 109 3,977
20 86 2,172
ED
None 135 7,523
Minimal 62 3,054
Moderate 29 834
Complete 35 994
ED
None/minimal 197 10,576
Moderate/complete 64 1,828
Trend test for ordinal variables; Wald chi-square test for binary variables.
CI  confidence interval; CVD  cardiovascular disease; ED  erectile dysfunction.
he Relationship Between ED andVD in Various Multivariate ModelsTable 3 T e Relationship Between ED andCVD in Various Multivariate Models
Model HR* 95% CI p Value†
Age-adjusted 1.42 1.05–1.90 0.02
Multivariate-adjusted‡ 1.41 1.05–1.90 0.02
Adjusted for age and continuous
Framingham risk score
1.40 1.04–1.88 0.03
Hazard ratio (HR) compared with men with no ED. †Wald chi-square test. ‡Themultivariate model
ncludes body mass index (continuous) and the variables that are part of the Framingham risk
core: age, high-density lipoprotein cholesterol, and total cholesterol (all as continuous variables),
s well as current smoking (yes/no), and hypertension categorized according to blood pressure
eadings by JNC-V definition (optimal, normal, high normal, stage I, and stage II to IV).
Abbreviations as in Tables 1 and 2.
If ED status in a multivariate statistical model are shown in
able 5. Several noteworthy observations can be made.
irst, among 902 men who did not develop CVD within 10
ears (non-CVD cases in this analysis), inclusion of ED
esulted in reclassification of 56 men (6.2%, 95% CI: 4.6%
o 7.8%); 39 of these men were reclassified into a lower risk
ategory and 17 were reclassified into a higher risk category.
econd, among 155 men who developed CVD within 10
ears, inclusion of ED resulted in reclassification of 17 men
11.0%, 95% CI: 6.1% to 15.9%); 8 of these men were
lassified into a lower risk category and the remaining 9 into
higher risk category. Based on this information, the net
eclassification improvement for ED was calculated as 3.1%
95% CI: –2.4% to 8.5%), which was not statistically
ignificant (p  0.27). An alternative measure of discrimi-
ation, the integrated discrimination improvement, was
stimated at 0.003 (95% CI: –0.001 to 0.008), which was
lso not statistically significant (p  0.13).
iscussion
n this prospective study of 40- to 70-year-old men followed
or 12 years, ED predicts the development of CVD,
e and ED Statusm Risk Score and ED Status
Age-Adjusted Incidence Rate
per 1,000 Person-Years 95% CI p Value*
20.9 18.9–23.6 0.001
0.001
10.3 6.5–16.3
13.8 10.4–18.1
26.4 22.0–31.7
31.8 25.2–40.2
0.08
20.0 17.0–23.5
19.1 15.2–24.1
29.2 20.8–41.1
25.1 17.6–35.6
0.02
19.7 17.3–22.5
26.9 20.9–34.7
iscrimination of CVD inarious Multivariate ModelsTable 4 Discrimination of CVD inVarious Multivariate Models
Model C Statistic (95% CI)
Multivariate* 0.7068 (0.6769–0.7366)
Multivariate*  ED 0.7106 (0.6804–0.7408)
Age  continuous Framingham risk score 0.6910 (0.6604–0.7216)
Age  continuous Framingham risk score  ED 0.6953 (0.6645–0.7261)
The multivariate model includes body mass index (continuous) and the variables that are part of
he Framingham risk score: age, high-density lipoprotein cholesterol, and total cholesterol (all as
ontinuous variables), as well as current smoking (yes/no), and hypertension categorized accord-
ng to blood pressure readings by JNC-V definition (optimal, normal, high normal, stage I, and stageScoringhaI to IV).
Abbreviations as in Tables 1 and 2.
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Does ED Improve CVD Risk Prediction? January 26, 2010:350–6ndependent of age, traditional risk factors, and Framing-
am risk score. In models adjusted for established risk
actors, men with ED have a 40% higher risk of developing
VD than men without ED. Contrary to our hypothesis,
nd in spite of the statistical significance of the association
etween ED and CVD, we are not able to confirm that ED
mproves the prediction of CVD incidence in middle-aged
nd older men beyond that offered by the Framingham risk
core. This is perhaps expected given the strength of the
ssociation between traditional risk factors and CVD, the
elative magnitude of the observed HR associated with ED,
nd that numerous studies have shown that the factors that
omprise the Framingham risk score are associated with ED
tself (6,20–25).
In both low (32,33) and high (30,58,59) cardiovascular
isk populations, ED has been shown to predict a composite
nd point of various adverse cardiac events. Montorsi et al.
8), in a sample of 285 patients with coronary artery disease,
howed that extent of coronary artery disease is related to
everity of ED. In their study (8), ED generally preceded
resentation of CAD by 2 to 3 years on average. Among
en with type 2 diabetes who did not have clinically overt
VD, the presence of ED predicted CHD events (59). A
istorical cohort study based on medical records data (60)
howed that ED significantly predicted CVD in the period
efore the introduction of sildenafil, but not afterward.
hree large prospective cohort studies have shown that ED
redicts CVD. In the PCPT (Prostate Cancer Prevention
rial) study (32), the multivariate-adjusted HR for ED was
.45, which was independent of age and other CVD risk
actors. Indeed, PCPT data show that ED was as strongly
elated to CVD as some traditional CVD risk factors. In the
rimpen Study (33), the age- and Framingham-adjusted
R was 1.6 (95% CI: 1.2 to 2.3) for reduced erectile rigidity
nd 2.6 (95% CI: 1.3 to 5.2) for severely reduced erectile
igidity. Using data from the Olmstead County Study,
nman et al. (31) have recently shown that ED was
ssociated with an approximately 80% higher risk of subse-
uent coronary artery disease. The association of ED with
oronary artery disease in that study was particularly strong
mong younger men; this is unlike the current study, in
umber of Subjects According to CVD Risk Category, With Reclassf Risk Category After Inclusion of E Status in a Multivariat StatTable 5 Number of Subjects According to CVD Risk Category,of Risk Category After Inclusion of ED Status in a Mul
10-Yr CV
Non-CVD Cases
10-Yr CVD Probability <5% 5%–<10% 10%–<20% >20%
5% 27 3 0 0
5%–10% 1 111 2 0
10%–20% 0 11 327 12
20% 0 0 27 381
Total 28 125 356 393
stimates of probabilities using Framingham risk score (rows) and with Framingham risk score plu
or age. Bold values indicate subjects not reclassified. *n  106 of the 261 CVD cases had an ev
Abbreviations as in Tables 1 and 2.hich the association between ED and CVD was consistent ocross age groups. Despite the fact that all 3 large prospec-
ive cohort studies observed a significant association of ED
ith CVD independent of risk factors, as observed in this
eport, none assessed whether ED improved the prediction
f CVD using reclassification statistics.
The biological mechanisms linking ED and CVD are
elatively well-established. Endothelial dysfunction, charac-
erized by impaired nitric oxide bioavailability, precedes the
evelopment of atherosclerotic lesions and has been sug-
ested as an important link between ED and CVD
3,6,8,14–19,61). The penile corpora may be more suscep-
ible to the consequences of reduced vasodilation and blood
ow reserve than the heart or brain given the smaller
iameter of the penile arteries (29). In addition, the periph-
ral cavernosal arteries are end arteries, and thus do not have
he ability to form collaterals to compensate for decreased
lood flow, as does the heart (62). Thus, loss of vasodilation
ay be recognized earlier in the microvascular penile bed
han in coronary arteries.
tudy limitations. Limitations to the current study should
e acknowledged. Perhaps the most important limitation
oncerns the measurement of ED. The ED variable used in
his report was derived from an ED self-assessment, widely
onsidered the gold standard, performed during the second
xamination; it was not measured directly. Unfortunately,
he self-assessment was not included at baseline. Also, we
ere not able to confirm 61 CVD self-reports with objective
nformation. Nonetheless, in a sensitivity analysis where all
nconfirmed self-reported CVD events were coded as
oncases, the multivariate-adjusted HR associated with ED
1.37, 95% CI: 0.98 to 1.90) was similar in magnitude to the
R that included unconfirmed events, suggesting no bias in
he estimate due to inclusion of self-reported CVD events.
nother concern is that MMAS included mostly white men
f higher socioeconomic status, so these results may not be
eneralizable to more diverse populations. However,
MAS was representative of the greater Boston, Massa-
husetts, male population at the time of sampling (63).
lthough the low (52%) response rate at baseline is cause
or concern, a telephone survey of 206 nonrespondents to
MAS (42) showed that whereas nonrespondents were
tional ModelReclassification
ate Statistical Model
bability After Inclusion of ED Status
CVD Cases*
Total <5% 5%–<10% 10%–<20% >20% Total
30 46 2 0 0 48
114 4 37 3 0 44
350 0 2 36 4 42
408 0 0 2 19 21
902 50 41 41 23 155
atus (columns) are shown among CVD cases and non-CVD cases. Both models were also adjusted
0 years following baseline. These are considered noncases in this analysis.ificasticWi h
tivari
D Pro
s ED stlder, less likely to report cancer or heart disease, and more
l
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January 26, 2010:350–6 Does ED Improve CVD Risk Prediction?ikely to report their health as fair or poor compared with
he entire cohort, there were no differences in the prevalence
f diabetes, high blood pressure, history of prostate surgery,
r restriction in activity due to poor health. Furthermore,
he crude CVD incidence rate observed in this cohort (21.0
er 1,000 person-years) is nearly identical to the CVD
ncidence rate among men age 55 to 64 years in the
ramingham Heart Study (21.4 per 1,000 person-years)
64), suggesting that attrition and inclusion of self-reported
VD events did not bias our estimates.
These limitations must be considered in light of the
trengths of this study. These include a random, population-
ased sample of generally healthy, well-characterized men
rom a defined geographic area, the ability to statistically
djust for a number of factors that could confound the
ssociation between ED and CVD, as well as the length
f follow-up and the relatively sizable number of events.
e also used novel statistical methods that were designed
o assess the additional predictive utility of new markers
or disease outcomes and which extend traditional reclas-
ification estimates that ignore the direction of the
eclassification.
onclusions
he clinical implications of the current study are mixed. On
he one hand, this study provides confirmatory evidence that
D is a sentinel for CVD, independent of established risk
actors. On the other, we are unable to show that ED
ignificantly improves the prediction of who will develop
VD. Nonetheless, any reclassification would be useful
linically given that the assessment of ED is associated with
ittle cost and no risks. Thus, the threshold for demonstra-
ion of clinical utility for ED screening would need to be far
ower than for more expensive screening tests, such as
-reactive protein or coronary calcium. Finally, the present
ndings emphasize the need for primary care physicians and
ther health care providers to pay particular attention to the
ardiovascular risk profiles of their patients with ED, in
eeping with current recommendations (4,65).
eprint requests and correspondence: Dr. Andre B. Araujo,
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